A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan ; day:11 ; month:9 ; year:2023 ; pages:1-14
Annals of hematology ; (11.9.2023), 1-14

Creator
Horigome, Yuichi
Iino, Masaki
Harazaki, Yoriko
Kobayashi, Takahiro
Handa, Hiroshi
Hiramatsu, Yasushi
Kuroi, Taiga
Tanimoto, Kazuki
Matsue, Kosei
Abe, Masahiro
Ishida, Tadao
Ito, Shigeki
Iwasaki, Hiromi
Kuroda, Junya
Shibayama, Hirohiko
Sunami, Kazutaka
Takamatsu, Hiroyuki
Tamura, Hideto
Hayashi, Toshiaki
Akagi, Kiwamu
Maeda, Takahiro
Yoshida, Takahiro
Mori, Ikuo
Shinozaki, Tomohiro
Iida, Shinsuke
Contributor
SpringerLink (Online service)

DOI
10.1007/s00277-023-05428-7
URN
urn:nbn:de:101:1-2023112714100625431044
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Horigome, Yuichi
  • Iino, Masaki
  • Harazaki, Yoriko
  • Kobayashi, Takahiro
  • Handa, Hiroshi
  • Hiramatsu, Yasushi
  • Kuroi, Taiga
  • Tanimoto, Kazuki
  • Matsue, Kosei
  • Abe, Masahiro
  • Ishida, Tadao
  • Ito, Shigeki
  • Iwasaki, Hiromi
  • Kuroda, Junya
  • Shibayama, Hirohiko
  • Sunami, Kazutaka
  • Takamatsu, Hiroyuki
  • Tamura, Hideto
  • Hayashi, Toshiaki
  • Akagi, Kiwamu
  • Maeda, Takahiro
  • Yoshida, Takahiro
  • Mori, Ikuo
  • Shinozaki, Tomohiro
  • Iida, Shinsuke
  • SpringerLink (Online service)

Other Objects (12)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan

Related objects